sorafenib resistance
Original Article Long non-coding RNA CASC2 reduces sorafenib resistance in hepatocellular carcinoma cells via inhibition of miR-21-mediated PI3K/AKT pathways
... Presently, sorafenib, a multikinase inhibitor with antiangiogenic and antiproliferative eff- ects, is the only chemotherapy drug extensively used in clinical practice as a first-line treat- ment for advanced HCC ...
9
An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells
... Sorafenib resistance remains a major obstacle for the effective treatment of hepatocellular carcinoma (HCC), and a number of miRNAs contribute to this ...in sorafenib-resistant cells and participate ...
13
<p>LncRNA HEIH Confers Cell Sorafenib Resistance in Hepatocellular Carcinoma by Regulating miR-98-5p/PI3K/AKT Pathway</p>
... cisplatin resistance in ovarian cancer 27 and lung ...ulate sorafenib resistance in ...increased sorafenib resistance in non- responsive HCC ...to sorafenib treatment in HCC ...
11
Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism
... acquired resistance limits the application of sorafenib and its ...acquired resistance to ...of sorafenib to generate sorafenib-resistant cell lines, 786-O-R and ...to sorafenib, ...
13
<p>HANR Enhances Autophagy-Associated Sorafenib Resistance Through miR-29b/ATG9A Axis in Hepatocellular Carcinoma</p>
... that sorafenib-resistant HCC cell lines were successfully ...on sorafenib resistance of HCC cells, HepG2 and Huh7 cells were transfected with HANR overexpression ...with sorafenib for 24 h. ...
11
Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma
... of sorafenib treatment, levels of β-catenin and its downstream target genes including c- Myc and CyclinD1 were upregulated in SMMC-7721, MHCC-97H, and SK-Hep1 HCC cell lines (Additional file 1: Figure ...in ...
14
Original Article Valproic acid overcomes transforming growth factor- -mediated sorafenib resistance in hepatocellular carcinoma
... Abstract: Sorafenib is a multi-kinase inhibitor approved for hepatocellular carcinoma, but rarely causes tumor re- gression in patients with chronic liver ...in sorafenib resistance, HepG2 and ...
15
MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway
... that sorafenib induced autophagic death of HCC cells ...in sorafenib resistance, and that inhibition of autophagy sensitizes HCC cells to sorafenib ...regulate sorafenib ...
15
Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro
... of sorafenib resistance, and the c-Met-targeting drug PHA665752 inhibits its expres- sion in various HCC cell ...the sorafenib resistance of liver cancer cells ...induced sorafenib ...
12
Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p
... to sorafenib in vitro and in ...to sorafenib, and the effects of SNHG16 knockdown on sorafenib resistance could be blocked by miR-140-5p ...attenuated sorafenib resistance in HCC ...
8
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
... Our results have important implications. First, we show that cancer cells acquire EMT-like properties without a full mesenchy- mal switch, which facilitates infiltration of the liver tissue and vessel co-option. ...
13
<p>The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma</p>
... of sorafenib resistance in ...that sorafenib treatment promoted CSC-associated protein expression of the hepatoma cells, while the in vivo experiments showed that PLC/PRF/5 and HepG2 xenograft tumors ...
11
<p>ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance</p>
... In HCC cells, the transcription factor ETS-1, an important effector of HGF/c-MET signaling pathway, could function as a co-regulator of PXR and enhance sorafenib resistance. In the present work, we found ...
12
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
... of sorafenib-resistant HCC, and suggests that inhibition of FGF19/FGFR4 sig- naling may represent an attractive strategy for overcom- ing sorafenib resistance in ...
10
Original Article The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells
... Background: Sorafenib is one of the most commonly used systemic therapies for hepatocellular carci- noma (HCC), but the acquired resistance towards sorafenib found in HCC patients usually led to ...
9
Down Regulation of TGF β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib
... with sorafenib, and observed that many HCC cells survived treatment, even in the presence of high doses of sora- fenib, indicating low sensitivity of HCC cells to sorafenib and their resistance to ...
11
Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells
... whereas sorafenib treatment decreased the PET imaging in liver location of ...of sorafenib on intrahepatic growth of HCC ...group. Sorafenib treatment significantly attenuated the intrahepatic growth ...
10
Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma
... Abstract: Sorafenib is an oral multiple kinase inhibitor that blocks Raf, vascular endothelial growth factor receptor, and platelet-derived growth factor ...(HCC). Sorafenib has demonstrated a 44% increase ...
9
A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation
... the resistance to the EGFR- targeting antibody (cetuximab or panitumumab) helped to identify a group of patients that can benefit from this kind of treatment (patients with wild-type ...
10
<p>Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib</p>
... From January 2013 to January 2016, 249 cases of HCC patients treated with Sorafenib were collected, and the Response Evaluation Criteria in Solid Tumors (RECIST) were applied to evaluate the ef fi cacy of each ...
12